These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1027 related articles for article (PubMed ID: 34103407)

  • 1. Antibodies elicited by mRNA-1273 vaccination bind more broadly to the receptor binding domain than do those from SARS-CoV-2 infection.
    Greaney AJ; Loes AN; Gentles LE; Crawford KHD; Starr TN; Malone KD; Chu HY; Bloom JD
    Sci Transl Med; 2021 Jun; 13(600):. PubMed ID: 34103407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SARS-CoV-2 BA.4/5 infection triggers more cross-reactive FcγRIIIa signaling and neutralization than BA.1, in the context of hybrid immunity.
    Richardson SI; Mzindle N; Motlou T; Manamela NP; van der Mescht MA; Lambson BE; Everatt J; Amoako DG; Balla S; von Gottberg A; Wolter N; de Beer Z; de Villiers TR; Bodenstein A; van den Berg G; Abdullah F; Rossouw TM; Boswell MT; Ueckermann V; Bhiman JN; Moore PL
    J Virol; 2024 Jul; 98(7):e0067824. PubMed ID: 38953380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The SARS-CoV-2 mRNA-1273 vaccine elicits more RBD-focused neutralization, but with broader antibody binding within the RBD.
    Greaney AJ; Loes AN; Gentles LE; Crawford KHD; Starr TN; Malone KD; Chu HY; Bloom JD
    bioRxiv; 2021 Apr; ():. PubMed ID: 33880474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and immunogenicity of a modified mRNA-lipid nanoparticle vaccine candidate against COVID-19: Results from a phase 1, dose-escalation study.
    Essink BJ; Shapiro C; Isidro MGD; Bradley P; Pragalos A; Bloch M; Santiaguel J; Frias MV; Miyakis S; Alves de Mesquita M; Berrè S; Servais C; Waugh N; Hoffmann C; Baba E; Schönborn-Kellenberger O; Wolz OO; Koch SD; Ganyani T; Boutet P; Mann P; Mueller SO; Ramanathan R; Gaudinski MR; Vanhoutte N
    Hum Vaccin Immunother; 2024 Dec; 20(1):2408863. PubMed ID: 39422261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and immunogenicity of an egg-based inactivated Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomized, placebo-controlled, phase 1/2 trial in Vietnam.
    Duc Dang A; Dinh Vu T; Hai Vu H; Thanh Ta V; Thi Van Pham A; Thi Ngoc Dang M; Van Le B; Huu Duong T; Van Nguyen D; Lawpoolsri S; Chinwangso P; McLellan JS; Hsieh CL; Garcia-Sastre A; Palese P; Sun W; Martinez JL; Gonzalez-Dominguez I; Slamanig S; Manuel Carreño J; Tcheou J; Krammer F; Raskin A; Minh Vu H; Cong Tran T; Mai Nguyen H; Mercer LD; Raghunandan R; Lal M; White JA; Hjorth R; Innis BL; Scharf R
    Vaccine; 2022 Jun; 40(26):3621-3632. PubMed ID: 35577631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A self-amplifying RNA vaccine protects against SARS-CoV-2 (D614G) and Alpha variant of concern (B.1.1.7) in a transmission-challenge hamster model.
    Frise R; Baillon L; Zhou J; Kugathasan R; Peacock TP; Brown JC; Samnuan K; McKay PF; Shattock RJ; Barclay WS
    Vaccine; 2022 May; 40(20):2848-2855. PubMed ID: 35396165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Omicron variant Spike-specific antibody binding and Fc activity are preserved in recipients of mRNA or inactivated COVID-19 vaccines.
    Bartsch YC; Tong X; Kang J; Avendaño MJ; Serrano EF; García-Salum T; Pardo-Roa C; Riquelme A; Cai Y; Renzi I; Stewart-Jones G; Chen B; Medina RA; Alter G
    Sci Transl Med; 2022 Apr; 14(642):eabn9243. PubMed ID: 35289637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvants to the S1-subunit of the SARS-CoV-2 spike protein vaccine improve antibody and T cell responses and surrogate neutralization in mice.
    Becker W; Rebbani K; Duan Z; Valkov E; Bryant S; Ho M; Berzofsky JA; Olkhanud PB
    Sci Rep; 2024 Nov; 14(1):29609. PubMed ID: 39609527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma.
    Cele S; Gazy I; Jackson L; Hwa SH; Tegally H; Lustig G; Giandhari J; Pillay S; Wilkinson E; Naidoo Y; Karim F; Ganga Y; Khan K; Bernstein M; Balazs AB; Gosnell BI; Hanekom W; Moosa MS; ; ; Lessells RJ; de Oliveira T; Sigal A
    Nature; 2021 May; 593(7857):142-146. PubMed ID: 33780970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cross-Reactive Antibody Responses to Coronaviruses Elicited by SARS-CoV-2 Infection or Vaccination.
    Lee RSH; Cheng SMS; Zhao J; Tsoi AYS; Lau KKM; Chan CHC; Li JKC; Hui DSC; Peiris M; Yen HL
    Influenza Other Respir Viruses; 2024 May; 18(5):e13309. PubMed ID: 38725111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preserved recognition of Omicron spike following COVID-19 messenger RNA vaccination in pregnancy.
    Bartsch YC; Atyeo C; Kang J; Cai Y; Chen B; Gray KJ; Edlow AG; Alter G
    Am J Obstet Gynecol; 2022 Sep; 227(3):493.e1-493.e7. PubMed ID: 35430229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody responses induced by SHIV infection are more focused than those induced by soluble native HIV-1 envelope trimers in non-human primates.
    van Schooten J; van Haaren MM; Li H; McCoy LE; Havenar-Daughton C; Cottrell CA; Burger JA; van der Woude P; Helgers LC; Tomris I; Labranche CC; Montefiori DC; Ward AB; Burton DR; Moore JP; Sanders RW; Crotty S; Shaw GM; van Gils MJ
    PLoS Pathog; 2021 Aug; 17(8):e1009736. PubMed ID: 34432859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced sensitivity of the SARS-CoV-2 Lambda variant to monoclonal antibodies and neutralizing antibodies induced by infection and vaccination.
    Wang M; Zhang L; Li Q; Wang B; Liang Z; Sun Y; Nie J; Wu J; Su X; Qu X; Li Y; Wang Y; Huang W
    Emerg Microbes Infect; 2022 Dec; 11(1):18-29. PubMed ID: 34818119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccine preventable diseases and vaccination coverage in Aboriginal and Torres Strait Islander people, Australia 2006-2010.
    Naidu L; Chiu C; Habig A; Lowbridge C; Jayasinghe S; Wang H; McIntyre P; Menzies R
    Commun Dis Intell Q Rep; 2013 Dec; 37 Suppl():S1-95. PubMed ID: 24410428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Qualitative evidence synthesis informing our understanding of people's perceptions and experiences of targeted digital communication.
    Ryan R; Hill S
    Cochrane Database Syst Rev; 2019 Oct; 10(10):ED000141. PubMed ID: 31643081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies.
    Greaney AJ; Starr TN; Barnes CO; Weisblum Y; Schmidt F; Caskey M; Gaebler C; Cho A; Agudelo M; Finkin S; Wang Z; Poston D; Muecksch F; Hatziioannou T; Bieniasz PD; Robbiani DF; Nussenzweig MC; Bjorkman PJ; Bloom JD
    Nat Commun; 2021 Jul; 12(1):4196. PubMed ID: 34234131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. One dose of COVID-19 nanoparticle vaccine REVC-128 protects against SARS-CoV-2 challenge at two weeks post-immunization.
    Gu M; Torres JL; Li Y; Van Ry A; Greenhouse J; Wallace S; Chiang CI; Pessaint L; Jackson AM; Porto M; Kar S; Li Y; Ward AB; Wang Y
    Emerg Microbes Infect; 2021 Dec; 10(1):2016-2029. PubMed ID: 34651563
    [No Abstract]   [Full Text] [Related]  

  • 18. Molecular engineering of a cryptic epitope in Spike RBD improves manufacturability and neutralizing breadth against SARS-CoV-2 variants.
    Rodriguez-Aponte SA; Dalvie NC; Wong TY; Johnston RS; Naranjo CA; Bajoria S; Kumru OS; Kaur K; Russ BP; Lee KS; Cyphert HA; Barbier M; Rao HD; Rajurkar MP; Lothe RR; Shaligram US; Batwal S; Chandrasekaran R; Nagar G; Kleanthous H; Biswas S; Bevere JR; Joshi SB; Volkin DB; Damron FH; Love JC
    Vaccine; 2023 Jan; 41(5):1108-1118. PubMed ID: 36610932
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 52.